RT @NorthTxMSG: Conclusion: The use of carfilzomib in RRMM pts significantly increases risk of developing congestive heart failure. Clinic…
RT @NorthTxMSG: Conclusion: The use of carfilzomib in RRMM pts significantly increases risk of developing congestive heart failure. Clinic…
RT @NorthTxMSG: Conclusion: The use of carfilzomib in RRMM pts significantly increases risk of developing congestive heart failure. Clinic…
RT @NorthTxMSG: Conclusion: The use of carfilzomib in RRMM pts significantly increases risk of developing congestive heart failure. Clinic…
RT @NorthTxMSG: Conclusion: The use of carfilzomib in RRMM pts significantly increases risk of developing congestive heart failure. Clinic…
Conclusion: The use of carfilzomib in RRMM pts significantly increases risk of developing congestive heart failure. Clinicians shld be cautious about the risk of CHF associated w/ carfilzomib to ⬆️ benefits & ⬇️ the toxicities. #mmsm 👇 https://t.co/8